Xianming Deng
Guangzhou University of Chinese Medicine(CN)Target (United States)(US)Xiamen University(CN)Peking University(CN)Zhengzhou University of Light Industry(CN)China University of Mining and Technology(CN)First Affiliated Hospital of Xiamen University(CN)Ministry of Education(SA)Jiangsu Vocational College of Medicine(CN)Feed Control (Norway)(NO)Institute of Macromolecular Chemistry(UA)Jiangsu Provincial Academy of Traditional Chinese Medicine(CN)Zhongshan Hospital of Xiamen University(CN)Peking University Third Hospital(CN)Jiangsu Provincial Hospital of Traditional Chinese Medicine(CN)Life University(US)
Publications by Year
Research Areas
Protein Kinase Regulation and GTPase Signaling, Ubiquitin and proteasome pathways, Chronic Myeloid Leukemia Treatments, Melanoma and MAPK Pathways, Protein Degradation and Inhibitors
Most-Cited Works
- → Systematic identification of genomic markers of drug sensitivity in cancer cells(2012)2,534 cited
- → A Landscape of Pharmacogenomic Interactions in Cancer(2016)2,211 cited
- → Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity(2018)756 cited
- → Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders(2017)701 cited
- → Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors(2010)596 cited
- → Low-dose metformin targets the lysosomal AMPK pathway through PEN2(2022)577 cited